{"id":103302,"date":"2021-12-23T01:56:52","date_gmt":"2021-12-23T01:56:52","guid":{"rendered":"https:\/\/localhost\/lock-stock\/memphasys\/\/?p=103302"},"modified":"2022-06-20T06:57:40","modified_gmt":"2022-06-19T20:57:40","slug":"operational-update","status":"publish","type":"post","link":"https:\/\/www.memphasys-felix-japan.com\/ja\/operational-update\/","title":{"rendered":"Operational Update<\/span>"},"content":{"rendered":"
<\/p>\n

Commercial sales for Felix device into initial markets anticipated to commence mid to late CY20201<\/sup><\/strong><\/p>\n

 \u00a0<\/span><\/span>Highlights: \u00a0<\/span><\/p>\n

    \n
  • Initial commercial pathway to focus on selected countries aligned to the Company\u2019s commercialisation objectives of seeking early commercial sales timeframes \u00a0<\/span><\/li>\n
  • These major and\/ or strategic markets include Japan, India, Canada, Iran and New Zealand \u00a0<\/span><\/li>\n
  • Memphasys currently has agreements for early Felix clinical assessments in place with Key Opinion Leaders (KOLs) in all of these countries except for New Zealand. Discussions with New Zealand-based clinics and centres in progress \u00a0<\/span><\/li>\n
  • Verification and Validation (V&V) process, required to be completed before commercial sales can commence, is underway and expected to be completed by mid CY2020 \u00a0<\/span><\/li>\n
  • Felix device remains on-track for commercial sales in mid to late CY20201 \u00a0<\/span><\/span><\/li>\n<\/ul>\n

     \u00a0<\/span><\/span>Australian-based bio-separations company Memphasys Limited (ASX: MEM) (\u00e2\u20ac\u0153Memphasys\u00e2\u20ac\u009d or \u00e2\u20ac\u0153the Company\u00e2\u20ac\u009d) confirms that together with its regulatory advisor it has undertaken and now completed a review of international regulatory environments, identifying five countries to be the focus to target initial commercial sales of the Felix device – a unique device for separating high quality sperm from a semen sample for use in human IVF procedures. \u00a0<\/span><\/p>\n

    These key markets, which include Japan, India, Canada, and New Zealand, have a regulatory framework that aligns to the Company\u2019s commercialisation objectives of seeking early commercial sales timeframes. Memphasys expects to achieve first commercial sales of the Felix device in mid to late CY20201 <\/span>(See ASX Announcement: 6\/11\/19). \u00a0<\/span><\/p>\n

    Commenting on the confirmation of the initial commercial pathway for the Felix device, Memphasys Executive Chair Alison Coutts said: \u00a0<\/span><\/p>\n

    \u00e2\u20ac\u0153The identification of these markets demonstrates the path to commercial sales is becoming clearer, with a series of regulatory factors being a determinant in identifying these early-access targets. \u00a0<\/span><\/p>\n

    \u00e2\u20ac\u0153With the Felix KOL evaluation program underway and cartridges and consoles continuing to be produced, Memphasys is moving quickly to introduce the Felix device throughout the international IVF market.\u00e2\u20ac\u009d \u00a0<\/span><\/p>\n

    Memphasys has Key Opinion Leader (KOL) agreements in place in four of the five early-access target markets. Subject to positive results from the KOL assessments and achieving regulatory clearance in these markets (if required), these assessments will bolster the Felix data available to the Company and offer a ready-made reference customer base for accelerating early sales. \u00a0<\/span><\/p>\n

    The Company is in discussions with New Zealand-based clinics and centres with regards to appointing another KOL, which will see Memphasys hold a presence in all these early-access target markets. \u00a0<\/span><\/p>\n

    These five markets are highly attractive for Memphasys, with a recently released independent research report2 <\/span>concluding these counties will continue to support both a sizable and rising number of IVF procedures each year. \u00a0<\/span><\/p>\n

    While no country-specific data was available for Iran, the Middle Eastern region is deemed to be a growth market for IVF services, with the region as a whole completing 81,350 fresh IVF cycles in 2018. The region is expected to complete 128,340 fresh IVF cycles by 2026. \u00a0<\/span><\/p>\n

    Memphasys has commenced the verification and validation (\u00e2\u20ac\u0153V&V\u00e2\u20ac\u009d) process, required to be completed before commercial sales can commence, and expects it to be completed by mid-CY2020. \u00a0<\/span><\/p>\n

    \n<\/div><\/div><\/div><\/div><\/div><\/div>